The SoftBank-backed biological analysis technology provider priced its shares above its range and will likely close the offering at $449m.
10x Genomics, a US-based biotechnology instrument provider backed by internet and telecommunications conglomerate SoftBank, raised $390m in an initial public offering on the Nasdaq Global Select Market yesterday.
The company priced 10 million shares at $39.00 each, above the IPO’s $31 to $35 range. The underwriters have the 30-day option to buy another 1.5 million shares, which would boost its size to approximately $449m.
Founded in 2012, 10x produces instruments and software and that help researchers study biological systems…
